Your browser doesn't support javascript.
loading
Correction: Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy.
Gialeli, Chrysostomi; Tuysuz, Emre Can; Staaf, Johan; Guleed, Safa; Paciorek, Veronika; Mörgelin, Matthias; Papadakos, Konstantinos S; Blom, Anna M.
Affiliation
  • Gialeli C; Department of Translational Medicine, Lund University, Malmö, Sweden.
  • Tuysuz EC; Experimental Cardiovascular Research Group, Department of Clinical Sciences, Lund University, Malmö, Sweden.
  • Staaf J; Department of Translational Medicine, Lund University, Malmö, Sweden.
  • Guleed S; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, Lund, Sweden.
  • Paciorek V; Department of Translational Medicine, Lund University, Malmö, Sweden.
  • Mörgelin M; Department of Translational Medicine, Lund University, Malmö, Sweden.
  • Papadakos KS; Colzyx AB, Lund, Sweden.
  • Blom AM; Department of Translational Medicine, Lund University, Malmö, Sweden.
J Exp Clin Cancer Res ; 42(1): 135, 2023 May 30.
Article in En | MEDLINE | ID: mdl-37248519
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Exp Clin Cancer Res Year: 2023 Document type: Article Affiliation country: Suecia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Exp Clin Cancer Res Year: 2023 Document type: Article Affiliation country: Suecia